Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2016. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) under the GlaxoSmithKline US Deferred Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to disclosure of specific share transactions and does not contain financial statements or performance metrics.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses the acquisition of American Depositary Shares (ADSs) by specific executives following a dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is a compliance notification regarding Rule 12g3-2(b) and Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Acquisition of ADSs via dividend reinvestment on January 28, 2016.
- Price: $40.28 per ADS.
- Participants: Dr. M M Slaoui (288.211 ADSs) and Mr. D E Troy (387.755 ADSs).
- Dividend Date: The reinvestment followed a dividend paid to shareholders on January 14, 2016.
- Signatory: Victoria Whyte, Company Secretary, signed on February 1, 2016.